Recent Submissions

  • Expert Reference Group: Interval Cancer Report CervicalCheck

    National Screening Service; CervicalCheck (Health Service Executive, 2020-10)
  • Expert Reference Group: Interval Cancer Report BowelScreen

    National Screening Service; BowelScreen: the National Bowel Screening Programme (Health Service Executive, 2020-10-20)
  • National Clinical Guideline - Diagnosis and staging of patients with Prostate Cancer

    Corporate Services; Dr Eve O�Toole, Head of Evidence and Quality Hub, NCCP; guidelines@cancercontrol.ie (National Cancer Control Programme, 07/07/2022)
  • National Clinical Guideline � Diagnosis, staging and treatment of patients with Gestational Trophoblastic Disease

    National Community Operations; Dr Eve O�Toole, Head of Evidence and Quality Hub, NCCP; guidelines@cancercontrol.ie (National Cancer Control Programme, 13/05/2022)
  • Association of treatment-emergent symptoms identified by patient-reported outcomes with adjuvant endocrine therapy discontinuation.

    Smith, Karen Lisa; Verma, Neha; Blackford, Amanda L; Lehman, Jennifer; Westbrook, Kelly; Lim, David; Fetting, John; Wolff, Antonio C; Jelovac, Daniela; Miller, Robert S; et al. (2022-04-21)
  • Mitochondrial complex IV defects induce metabolic and signaling perturbations that expose potential vulnerabilities in HCT116 cells.

    Uchenunu, Oro; Zhdanov, Alexander V; Hutton, Phillipe; Jovanovic, Predrag; Wang, Ye; Andreev, Dmitry E; Hulea, Laura; Papadopoli, David J; Avizonis, Daina; Baranov, Pavel V; et al. (2022-04-01)
    Mutations in genes encoding cytochrome c oxidase (mitochondrial complex IV) subunits and assembly factors [e.g., synthesis of cytochrome c oxidase 2 (SCO2)] are linked to severe metabolic syndromes. Notwithstanding that SCO2 is under transcriptional control of tumor suppressor p53, the role of mitochondrial complex IV dysfunction in cancer metabolism remains obscure. Herein, we demonstrate that the loss of SCO2 in HCT116 colorectal cancer cells leads to significant metabolic and signaling perturbations. Specifically, abrogation of SCO2 increased NAD+ regenerating reactions and decreased glucose oxidation through citric acid cycle while enhancing pyruvate carboxylation. This was accompanied by a reduction in amino acid levels and the accumulation of lipid droplets. In addition, SCO2 loss resulted in hyperactivation of the insulin-like growth factor 1 receptor (IGF1R)/AKT axis with paradoxical downregulation of mTOR signaling, which was accompanied by increased AMP-activated kinase activity. Accordingly, abrogation of SCO2 expression appears to increase the sensitivity of cells to IGF1R and AKT, but not mTOR inhibitors. Finally, the loss of SCO2 was associated with reduced proliferation and enhanced migration of HCT116 cells. Collectively, herein we describe potential adaptive signaling and metabolic perturbations triggered by mitochondrial complex IV dysfunction.
  • IL-36 signalling enhances a pro-tumorigenic phenotype in colon cancer cells with cancer cell growth restricted by administration of the IL-36R antagonist.

    Baker, Kevin; O'Donnell, Charlotte; Bendix, Maura; Keogh, Samuel; Byrne, James; O'Riordain, Michael; Neary, Peter; Houston, Aileen; Brint, Elizabeth (2022-04-01)
    The IL-36 cytokines are a recently described subset of the IL-1 family of cytokines, shown to play a role in the pathogenesis of intestinal diseases such as Inflammatory Bowel Disease (IBD). Given the link between IBD and colitis -associated cancer, as well as the involvement of other IL-1 family members in intestinal tumorigenesis, the aim of this work was to investigate whether IL-36 cytokines play a role in the pathogenesis of colon cancer. Whilst research to date has focused on the role of IL-36 family members in augmenting the immune response to induce tumour rejection, very little remains known about IL-36R signalling in tumour cells in this context. In this study we demonstrate that expression of IL-36 family member mRNA and protein are significantly increased in colorectal cancer tissue compared to adjacent non-tumour. In vitro assays showed stimulation of colon cancer cell lines with IL-36R agonists resulted in the activation of the pro-tumorigenic phenotypes of increased cellular migration, invasion and proliferation in both 2D and 3D models. In addition, the IL-36 cytokines induced strong expression of pro-inflammatory chemokines in both human and murine cell lines. Intraperitoneal injection of IL-36Ra significantly reduced tumour burden using the subcutaneous CT26 tumour model in syngeneic Balb/mice, and this was associated with a decrease in Ki-67 expression by tumour cells in the IL-36Ra- treated group relative to untreated, suggesting the inhibition of the pro-proliferative signalling of IL-36 agonists resulted in the decreased tumour size. Moreover, colon cancer cells lacking the IL-36R also showed reduced tumour growth and reduced Ki-67 expression in vivo. Taken together, this data suggests that targeting IL-36R signalling may be a useful targeted therapy for colorectal cancer patients with IL-36R+ tumour cells.
  • The SARS-CoV-2 Pandemic and Cancer Trials Ireland: Impact, Resolution and Legacy.

    O'Reilly, Seamus; Murphy, Verena; Mulroe, Eibhlin; Tucker, Lisa; Carragher, Fiona; Marron, Jacinta; Shannon, Aoife M; Rogan, Ken; Connolly, Roisin M; Hennessy, Bryan T; et al. (2022-04-30)
  • Interval cancer audit and disclosure in breast screening programmes: An international survey.

    Fitzpatrick, Patricia; Byrne, Helen; Flanagan, Fidelma; O'Doherty, Ann; Connors, Alissa; Larke, Aideen; O'Laoide, Risteard; Williams, Yvonne; Mooney, Therese (2022-09-07)
  • Survival and prognostic factors of isolated pulmonary metastases originating from colorectal cancer: An 8-year single-center experience.

    Balhareth, Ameera S; AlQattan, Abdullah S; Alshaqaq, Hassan M; Alkhalifa, Abdullah M; Al Abdrabalnabi, Alaa A; Alnamlah, Muna S; MacNamara, Deborah (2022-04-04)
  • Genetic and RNA-related molecular markers of trastuzumab-chemotherapy-associated cardiotoxicity in HER2 positive breast cancer: a systematic review.

    Lunardi, Mattia; Al-Habbaa, Ahmed; Abdelshafy, Mahmoud; Davey, Matthew G; Elkoumy, Ahmed; Ganly, Sandra; Elzomor, Hesham; Cawley, Christian; Sharif, Faisal; Crowley, James; et al. (2022-04-12)
  • Development and Validation of a Raman Spectroscopic Classification Model for Cervical Intraepithelial Neoplasia (CIN).

    Traynor, Damien; Duraipandian, Shiyamala; Bhatia, Ramya; Cuschieri, Kate; Tewari, Prerna; Kearney, Padraig; D'Arcy, Tom; O'Leary, John J; Martin, Cara M; Lyng, Fiona M (2022-04-06)
    The mortality associated with cervical cancer can be reduced if detected at the precancer stage, but current methods are limited in terms of subjectivity, cost and time. Optical spectroscopic methods such as Raman spectroscopy can provide a rapid, label-free and nondestructive measurement of the biochemical fingerprint of a cell, tissue or biofluid. Previous studies have shown the potential of Raman spectroscopy for cervical cancer diagnosis, but most were pilot studies with small sample sizes. The aim of this study is to show the clinical utility of Raman spectroscopy for identifying cervical precancer in a large sample set with validation in an independent test set. Liquid-based cervical cytology samples (n = 662) (326 negative, 200 cervical intraepithelial neoplasia (CIN)1 and 136 CIN2+) were obtained as a training set. Raman spectra were recorded from single-cell nuclei and subjected to a partial least squares discriminant analysis (PLSDA). In addition, the PLSDA classification model was validated using a blinded independent test set (n = 69). A classification accuracy of 91.3% was achieved with only six of the blinded samples misclassified. This study showed the potential clinical utility of Raman spectroscopy with a good classification of negative, CIN1 and CIN2+ achieved in an independent test set.
  • Colorectal microbiota after removal of colorectal cancer.

    Cronin, Peter; Murphy, Clodagh L; Barrett, Maurice; Ghosh, Tarini Shankar; Pellanda, Paola; O'Connor, Eibhlis M; Zulquernain, Syed Akbar; Kileen, Shane; McCourt, Morgan; Andrews, Emmet; et al. (2022-04-08)
    The colonic microbiome has been implicated in the pathogenesis of colorectal cancer (CRC) and intestinal microbiome alterations are not confined to the tumour. Since data on whether the microbiome normalises or remains altered after resection of CRC are conflicting, we studied the colonic microbiota of patients after resection of CRC. We profiled the microbiota using 16S rRNA gene amplicon sequencing in colonic biopsies from patients after resection of CRC (n = 63) in comparison with controls (n = 52), subjects with newly diagnosed CRC (n = 93) and polyps (i = 28). The colonic microbiota after surgical resection remained significantly different from that of controls in 65% of patients. Genus-level profiling and beta-diversity confirmed two distinct groups of patients after resection of CRC: one with an abnormal microbiota similar to that of patients with newly diagnosed CRC and another similar to non-CRC controls. Consumption levels of several dietary ingredients and cardiovascular drugs co-varied with differences in microbiota composition suggesting lifestyle factors may modulate differential microbiome trajectories after surgical resection. This study supports investigation of the colonic microbiota as a marker of risk for development of CRC.
  • Refining Glioblastoma Surgery through the Use of Intra-Operative Fluorescence Imaging Agents.

    Netufo, Oluwakanyinsolami; Connor, Kate; Shiels, Liam P; Sweeney, Kieron J; Wu, Dan; O'Shea, Donal F; Byrne, Annette T; Miller, Ian S (2022-04-29)
  • National cancer strategy 2017-2026: Key performance indicators: December 2019

    Department of Health (DOH) (Department of Health (DOH), 2020-05-14)
  • National cancer strategy 2017-2026: Implementation report 2019

    Department of Health (DOH) (Department of Health (DOH), 2020-05-14)
  • Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function.

    van der Kooi, Anne-Lotte L F; van Dijk, Marloes; Broer, Linda; van den Berg, Marleen H; Laven, Joop S E; van Leeuwen, Flora E; Lambalk, Cornelis B; Overbeek, Annelies; Loonen, Jacqueline J; van der Pal, Helena J; et al. (2021-02-14)
  • National Screening Service Key Performance Indicator Metadata 2022

    Health Service Executive (HSE) (Health Service Executive, 2022-04-11)

View more